CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
ABSTRACT: Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies and mechanisms of resistance have yet to be fully delineated. We conducted a real-world retrospective study of commercial teclistamab, capturing both clinical outcomes and immune correlates of treatment response in a cohort of patients (n = 52) with advanced R/RMM. Teclistamab was highly effective with an overall response rate (ORR) of 64%, including an ORR of 50% for patients with prior anti-BCMA therapy. Pretreatment plasma cell BCMA expression levels had no bearing on response. However, comprehensive pretreatment immune profiling identified that effector CD8+ T-cell populations were associated with response to therapy and a regulatory T-cell population associated with nonresponse, indicating a contribution of immune status in outcomes with potential utility as a biomarker signature to guide patient management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Blood advances - 8(2024), 7 vom: 09. Apr., Seite 1600-1611 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Firestone, Ross S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 28.03.2024 Date Revised 06.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2023011225 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36371023X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36371023X | ||
| 003 | DE-627 | ||
| 005 | 20240406232037.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2023011225 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1367.xml |
| 035 | |a (DE-627)NLM36371023X | ||
| 035 | |a (NLM)37878808 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Firestone, Ross S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2024 | ||
| 500 | |a Date Revised 06.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a ABSTRACT: Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies and mechanisms of resistance have yet to be fully delineated. We conducted a real-world retrospective study of commercial teclistamab, capturing both clinical outcomes and immune correlates of treatment response in a cohort of patients (n = 52) with advanced R/RMM. Teclistamab was highly effective with an overall response rate (ORR) of 64%, including an ORR of 50% for patients with prior anti-BCMA therapy. Pretreatment plasma cell BCMA expression levels had no bearing on response. However, comprehensive pretreatment immune profiling identified that effector CD8+ T-cell populations were associated with response to therapy and a regulatory T-cell population associated with nonresponse, indicating a contribution of immune status in outcomes with potential utility as a biomarker signature to guide patient management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a B-Cell Maturation Antigen |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a McAvoy, Devin |e verfasserin |4 aut | |
| 700 | 1 | |a Shekarkhand, Tala |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano, Edith |e verfasserin |4 aut | |
| 700 | 1 | |a Hamadeh, Issam |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Menglei |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Wei Ge |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Dhwani |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Carlyn R |e verfasserin |4 aut | |
| 700 | 1 | |a Hultcrantz, Malin |e verfasserin |4 aut | |
| 700 | 1 | |a Mailankody, Sham |e verfasserin |4 aut | |
| 700 | 1 | |a Hassoun, Hani |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Urvi S |e verfasserin |4 aut | |
| 700 | 1 | |a Korde, Neha |e verfasserin |4 aut | |
| 700 | 1 | |a Maclachlan, Kylee H |e verfasserin |4 aut | |
| 700 | 1 | |a Landau, Heather J |e verfasserin |4 aut | |
| 700 | 1 | |a Scordo, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Gunjan L |e verfasserin |4 aut | |
| 700 | 1 | |a Lahoud, Oscar B |e verfasserin |4 aut | |
| 700 | 1 | |a Giralt, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Murata, Kazunori |e verfasserin |4 aut | |
| 700 | 1 | |a Hosszu, Kinga K |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Lesokhin, Alexander M |e verfasserin |4 aut | |
| 700 | 1 | |a Usmani, Saad Z |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 8(2024), 7 vom: 09. Apr., Seite 1600-1611 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:7 |g day:09 |g month:04 |g pages:1600-1611 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2023011225 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 7 |b 09 |c 04 |h 1600-1611 | ||